SCHEMBL5137356

SCHEMBL5137356

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1cccc(OC)c1)CC1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
C5AR1 P21730 1/20 0.42
ADORA2B P29275 1/20 0.39
ADORA1 P30542 1/20 0.39
TLR7 Q9NYK1 1/20 0.39
F2R P25116 2/20 0.38
ADORA2A P29274 1/20 0.37
NR1H2 P55055 1/20 0.37
NR1H3 Q13133 1/20 0.37
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
WDR5 P61964 2/20 0.36
HSP90AA1 P07900 1/20 0.36
HSP90AB1 P08238 1/20 0.36
CNR2 P34972 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CALM1 P0DP23 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL648304 0.93 C5AR1 (0.41) MEN1KMT2AC5AR1ADORA2BADORA1
SCHEMBL648532 0.93 C5AR1 (0.41) MEN1KMT2AC5AR1TLR7PDE4B
SCHEMBL5137905 0.92 IGF1R (0.43) MEN1KMT2AC5AR1ALDH1A1
SCHEMBL5137557 0.91 C5AR1 (0.42) MEN1KMT2AC5AR1SMN1; SMN2ALDH1A1
SCHEMBL648763 0.91 C5AR1 (0.40) MEN1KMT2AC5AR1PDE4BALDH1A1
SCHEMBL5135374 0.91 C5AR1 (0.40) MEN1KMT2AC5AR1
SCHEMBL5137864 0.90 C5AR1 (0.44) C5AR1ADORA2BADORA1ADORA2APDE4B
SCHEMBL648140 0.89 C5AR1 (0.44) MEN1KMT2AC5AR1SMN1; SMN2ALDH1A1
SCHEMBL650496 0.89 C5AR1 (0.40) MEN1KMT2AC5AR1
SCHEMBL5135433 0.88 C5AR1 (0.46) MEN1KMT2AC5AR1TLR7F2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed